Romanian stock indices turn red, Romgaz sheds most
Bosnia's Federation net electricity output up 12% y/y in Jan
Bosnia's net electricity output up 0.6% y/y in Dec
Croatia's industrial sales up 4% in 2023
Serbia to launch second auction round for 400 MW of renewables
Dec 06, 2023 16:35 EEST
December 6 (SeeNews) - U.S. drug research consulting group ProPharma, in partnership with a portfolio company of Odyssey Investment Partners, has acquired Croatia's contract research organisation (CRO) Clinres Farmacija to expand into Central and Eastern Europe, ProPharma said on Wednesday.
This move reinforces ProPharma's competitive position with a blend of high patient access and cost-effective clinical services, the company said in a press release.
You can subscribe to our M&A newsletter here
Financial details were not disclosed.
Zagreb-headquartered Clinres Farmacija was set up in 2004. On the domestic market, it is a leading CRO offering a comprehensive suite of services to biotech, pharmaceutical, and medical device companies. Clinres Farmacija specialises in phase II - IV clinical trials, and offers a full range of regulatory services. With a strong regional presence across Central and Eastern Europe, Clinres Farmacija operates extensively in Croatia, Bosnia and Herzegovina, Serbia, Romania, Bulgaria, North Macedonia, Montenegro, Georgia, and Albania.
According to data from Croatia’s court registry, Clinres Farmacija is owned by CEO Romana Kajfez and Tanja Kajfez Novak.
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options